1 terminated. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Terminated 1 |
Follow IC-MPGN: new trials by email Literature Review of IC-MPGN trials Research Report on IC-MPGN
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471 Danicopan - C3 Glomerulonephritis, C3 Glomerulopathy | Phase 2 | Terminated | Alexion Pharmaceuticals, Inc. | 22 | 2018-06-20 | 2023-08-21 |
Glomerulonephritis, Membranoproliferative (1)
Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Glomerulonephritis (1) · Immune System Diseases (1) · Kidney Diseases (1) · Male Urogenital Diseases (1) · Nephritis (1) · Urogenital Diseases (1) · Urologic Diseases (1)
danicopan (1)
Alexion Pharmaceuticals, Inc. (1)
Australia (1) · Belgium (1) · Italy (1) · Netherlands (1) · United States (1)
2017 (1)